

Prolactinoma

[View the current Prolactinoma InDepth page on BioPortfolio.com \(PDF\)](#)

(<http://www.bioportfolio.com/indepth/Prolactinoma.html>) - Regularly Updated.

A prolactinoma is a benign tumor of the pituitary gland that produces a hormone called prolactin. It is the most common type of pituitary tumor. Symptoms of prolactinoma are caused by too much prolactin in the blood or by pressure of the tumor on surrounding tissues. Prolactin stimulates the breast to produce milk during pregnancy. After delivery of the baby, a mother's prolactin levels fall unless she breast feeds her infant. Each time the baby nurses, prolactin levels rise to maintain milk production. Based on size, a prolactinoma can be classified as a microprolactinoma or macroprolactinoma. ([From the Wikipedia article Prolactinoma](#) .)

Recent Publications on Prolactinoma:



- [The role of serum PRL bioactivity evaluation in hyperprolactinaemic women with different menstrual disorders.](#)
*Objective. The objective of the study was to characterize the bioactivity...*13th November, 2009
Department of Gynecological Endocrinology, Poznan University of Medical- Gynecol Endocrinol. 2009;25(12):799-806.
- [Recent trends in the pathophysiology and treatment of pituitary adenomas\]](#)
*Recent molecular pathological investigations have elucidated the...*10th November, 2009
Department of Neurosurgery, Director of Stroke Center, Teikyo University- Brain Nerve. 2009 Aug;61(8):957-62.
- [Evolution of an Aggressive Prolactinoma into a Growth Hormone Secreting Pituitary Tumor Coincident with GNAS Gene Mutation.](#)
*Context: Mixed PRL- and GH-secreting pituitary adenomas are relatively...*6th November, 2009
Endocrinology and Diabetology Unit (A.G.L., G.M., E.P., P.B.P., A.S.),- J Clin Endocrinol Metab. 2009 Nov 4. ([DOI Direct Link](#))
- [Consistent bone marrow-derived cell mobilization following repeated short courses of granulocyte-colony-stimulating factor in patients with amyotrophic lateral sclerosis: results from a multicenter prospective trial.](#)
*Abstract Background and aims. The aim of this study was to evaluate and...*3rd November, 2009
Dip Medicina-Oncologia Sperimentale, SC Universitaria di Ematologia and- Cytotherapy. 2009 Nov 2.
- [Effects of fulvestrant, an estrogen receptor antagonist, on MMQ cells and its mechanism.](#)
*OBJECTIVES: Unlike the successful endocrine therapy of breast cancers and...*21st October, 2009
Capital Medical University, Beijing, China.- Neuro Endocrinol Lett. 2009;30(2):268-74.
- [\[Prolactinoma\]](#)
*Prolactin-secreting tumours (prolactinomas) are benign neoplasms...*14th October, 2009
Klinika Chorob Wewnetrznych i Farmakologii Klinicznej, Katedry- Przegl Lek. 2009;66(4):198-205.
- [A novel use of temozolomide in a patient with malignant prolactinoma.](#)

- We report a 64-year-old male who presented to our department in 2007 with...* 13th October, 2009
Department of Neurosurgery, Flinders Medical Centre, Flinders Drive,- J Clin Neurosci. 2009 Oct 7. ([DOI Direct Link](#))
- [Efficacy and safety of cabergoline as first line treatment for invasive giant prolactinoma.](#)
Although cabergoline is effective in the treatment of micro- and... 2nd October, 2009
Division of Endocrinology and Metabolism, Department of Internal Medicine,- J Korean Med Sci. 2009 Oct;24(5):874-8. Epub 2009 Sep 24. ([DOI Direct Link](#))
 - [Prolactinoma in children and adolescents.](#)
The evolution of prolactinomas in children and adolescents continues to be... 30th September, 2009
Endocrinology Unit, Department of Medicine, Hospital T. Alvarez, Buenos- Horm Res. 2009;72(4):197-205. Epub 2009 Sep 29. ([DOI Direct Link](#))
 - [Gamma knife radiosurgery: a safe and effective salvage treatment for pituitary tumors not controlled despite conventional radiotherapy.](#)
Objective: We report the use of "Gamma knife" radiosurgery (GK) in 25... 24th September, 2009
F Swords, Endocrinology, Norfolk and Norwich University Hospitals NHS- Eur J Endocrinol. 2009 Sep 22. ([DOI Direct Link](#))
 - [Bilateral SUNCT-like headache in a patient with prolactinoma responsive to lamotrigine.](#)
Short-lasting unilateral neuralgiform headache with conjunctival injection... 19th September, 2009
Institute of Neurology, Clinical Centre of Serbia, Belgrade, Serbia,- J Headache Pain. 2009 Sep 11. ([DOI Direct Link](#))
 - [The role of serum PRL bioactivity evaluation in hyperprolactinaemic women with different menstrual disorders.](#)
Objective. The objective of the study was to characterize the bioactivity... 17th September, 2009
Department of Gynecological Endocrinology, Poznan University of Medical- Gynecol Endocrinol. 2009 Sep 15:1-8. ([DOI Direct Link](#))
 - [Giant prolactinoma: Efficacy of medical management.](#)
Objective: To review our experience with D2-selective dopamine agonist... 26th August, 2009
Dept of Endocrinology, Seth G S Medical College and KEM Hospital, Mumbai- Endocr Pract. 2009 Aug 24:1-14. ([DOI Direct Link](#))
 - [Evidence for the partial dopamine-receptor agonist aripiprazole as a first-line treatment of psychosis in patients with iatrogenic or tumorigenic hyperprolactinemia.](#)
BACKGROUND: Antipsychotic drugs have many side effects, including... 19th August, 2009
correspondence and M.D., Friends Hospital, 4641 Roosevelt Boulevard,- Psychosomatics. 2009 Jul-Aug;50(4):317-24. ([DOI Direct Link](#))
 - [Aggressive pituitary adenomas occurring in young patients in a large Polynesian kindred with a germline R271W mutation in the AIP gene.](#)
OBJECTIVE: Mutations in the aryl hydrocarbon receptor-interacting protein... 18th August, 2009
Department of Endocrinology and Diabetes and Centre for Hormone Research,- Eur J Endocrinol. 2009 Nov;161(5):799-804. Epub 2009 Aug 14. ([DOI Direct Link](#))

BioNews Results for Prolactinoma

- [Morphological Changes Induced by Insulin-Like Growth Factor-I Gene Therapy in Pituitary Cell Populations in Experimental Prolactinomas](#)
Cells Tissues Organs: Nov 14 2009 5:01AM Matching: prolactinoma
- [Recurrence of hyperprolactinemia after withdrawal of dopamine agonist therapy](#)
Endocrine Today: Nov 10 2009 9:36PM Matching: prolactinoma
- [Efficacy and Safety of Cabergoline as First Line Treatment for Invasive Giant Prolactinoma](#)
MDLinx: Oct 7 2009 11:56AM Matching: prolactinoma
- [Prolactinoma in Children and Adolescents](#)



Prolactinoma Clinical Trials:

- [Clomiphene in Males With Prolactinomas and Persistent Hypogonadism](#)



Prolactinoma Patents:

- 6703392- [1,2,3,4-tetrahydroisoquinoline derivatives](#)
- 7041789- [RFRP-3 and DNA thereof](#)
- 7067519- [7,8,9,10-tetrahydro-6H-azepino, 6,7,8,9-tetrahydro-pyrido and 2,3-dihydro-2H-pyrrolo\[2,1-b\]-quinazolinone derivatives](#)
- 7078402- [Aminothioli ester compounds, pharmaceutical and cosmetics compositions containing same and uses thereof](#)
- 7078565- [Benzamide derivatives as antagonists of orexin receptors](#)
- 7094424- [Cationic lipid compositions targeting angiogenic endothelial cells](#)
- 7097829- [Transgenic cells transfected with pituitary tumor transforming gene \(PTTG\) expression vectors and uses therefor](#)
- 7135192- [Cationic lipid compositions targeting angiogenic endothelial cells](#)
- 7166608- [N-aroyle piperazine derivatives as orexin receptor antagonists](#)
- 7189757- [Treatment of sleep disorders using CNS target modulators](#)
- 7192723- [G protein-coupled receptor protein, its DNA and ligand thereof](#)
- 6995244- [Antagonists for human prolactin](#)
- 6992170- [Polypeptides and polynucleotides homologous to thymosin, ephrin a receptors, and fibromodulin](#)
- 6943160- [Morpholine derivatives as antagonists of orexin receptors](#)
- 6756055- [Cationic lipid compositions targeting angiogenic endothelial cells](#)
- 6827931- [Method for treating endocrine disorders](#)
- 6835380- [Antibodies against rat pituitary tumor transforming gene carboxy-terminal \(PTTG-C\) peptides](#)
- 6858586- [Pituitary tumor transforming gene \(PTTG\) carboxy-terminal peptides and methods of use thereof to inhibit neoplastic cellular proliferation and/or transformation](#)
- 6866837- [Radiolabeled peptides for the diagnosis and treatment of breast and prostate tumors and metastases of such tumors](#)
- 6890738- [Prolactin antagonists and uses thereof](#)
- 6894031- [Pituitary tumor transforming gene \(PTTG\) carboxy-terminal peptides and methods of use thereof to inhibit neoplastic cellular proliferation and/or transformation](#)
- 6909030- [PTTG knockout rodent as a model to study mechanisms for various physiological](#)

- [phenomena, including diabetes](#)
- 6913926- [Method of regulating biological activity of pituitary tumor transforming gene \(PTTG\)1 using PTTG2](#)
 - 6939544- [Antibodies against mouse pituitary tumor transforming gene carboxy-terminal \(PTTG-C\) peptides](#)
 - 7192950- [Benzazepines and related heterocyclic derivatives which are useful as orexin receptor antagonists](#)
 - 7193033- [Peptide having appetite stimulating activity](#)
 - 7411051- [Antibodies to HDPPA04 polypeptide](#)
 - 7423052- [Piperidine compounds for use as orexin receptor antagonist](#)
 - 7432270- [N-aroyl cyclic amines](#)
 - 7435815- [Sulfonylamino-acetic acid derivatives](#)
 - 7468367- [Ethylene diamine derivatives and their use as orexin-receptor antagonists](#)
 - 7470710- [N-aroyl cyclic amine derivatives as orexin receptor antagonists](#)
 - 7494666- [Cationic lipid compositions targeting angiogenic endothelial cells](#)
 - 7517853- [Somatostatin-dopamine chimeric analogs](#)
 - 7538109- [Quinoxalin-3-one derivatives as orexin receptor antagonists](#)
 - 7566777- [Genes encoding hormone and lytic peptides](#)
 - 7405217- [N-aroyl piperazine derivatives as orexin receptor antagonists](#)
 - 7368531- [Human secreted proteins](#)
 - 7368527- [HADDE71 polypeptides](#)
 - 7217808- [RFRP-3 and DNA thereof](#)
 - 7241769- [Pyrimidines as PLK inhibitors](#)
 - 7268212- [Ligand of G protein-coupled receptor protein and DNA thereof](#)
 - 7279578- [Sulfonylamino-acetic acid derivatives](#)
 - 7285392- [Methods for identifying active compounds](#)
 - 7317026- [CNS target modulators](#)
 - 7326733- [Methods for increasing bone density](#)
 - 7345022- [Anti-fibril peptides](#)
 - 7355042- [Treatment of CNS disorders using CNS target modulators](#)
 - 7365077- [Piperazine bis-amide derivatives and their use as antagonists of the orexin receptor](#)
 - 7569561- [2,4-diaminopyrimidines useful for treating cell proliferation diseases](#)

Resources from the [NCBI](#) used in this document, [NCBI's standard disclaimer applies](#).

Nothing in this document should be used in place of personal medical advice from your own qualified medical practitioner. See BioPortfolio.com [User Agreement](#)

Send comments and feedback to:

Peter Barfoot Managing Director, BioPortfolio Ltd.

UK Tel: (+44) 1300 321501

USA Voicemail and Fax: (+1) 415 680 2472

[Peter Barfoot peter.barfoot@bioportfolio.com](mailto:peter.barfoot@bioportfolio.com)

All rights reserved. All other trademarks recognized.

BioPortfolio Limited is registered in England & Wales at Stafford House, 10 Prince of Wales Road, Dorchester, Dorset, DT1 1PW, UK. No.3312883 VAT No. GB 744 6483 10

Copyright 1997-2009 - BioPortfolio Limited.

